OBJECTIVE: To investigate the risk of radiation-induced secondary malignancy in patients with prostate cancer. METHODS: We identified 690 references from PubMed, Embase and the Cochrane Library before August 1, 2012, that reported secondary malignancy in patients with prostate cancer after receiving radiation therapy (RT), and finally four studies were included. We calculated summary estimates using random-effects meta-analysis. RESULTS: The overall standardized incidence ratio (SIR) of secondary malignancy in patients with prostate cancer receiving RT to the general population was 1.14 (95% CI 1.04-1.32). In the subgroup analysis, no increment in radiation-induced secondary malignancy risk was detected. In terms of SIR with different follow-up intervals, there was no difference in SIR (>6 months; <5 years) (SIR = 1.19, 95% CI 0.75-1.89) and SIR (>5 years; <10 years) (SIR = 1.39, 95% CI 0.87-2.23). When the follow-up extended to >10 years, a significantly increased secondary malignancy risk was observed (SIR = 1.45, 95% CI 1.23-1.72). There is no significantly increased secondary malignancy risk in patients receiving no RT. CONCLUSION: RT is associated with increased secondary malignancy in patients with prostate cancer; this effect only become conspicuous more than 10 years after treatment. 2014 S. Karger AG, Basel.
OBJECTIVE: To investigate the risk of radiation-induced secondary malignancy in patients with prostate cancer. METHODS: We identified 690 references from PubMed, Embase and the Cochrane Library before August 1, 2012, that reported secondary malignancy in patients with prostate cancer after receiving radiation therapy (RT), and finally four studies were included. We calculated summary estimates using random-effects meta-analysis. RESULTS: The overall standardized incidence ratio (SIR) of secondary malignancy in patients with prostate cancer receiving RT to the general population was 1.14 (95% CI 1.04-1.32). In the subgroup analysis, no increment in radiation-induced secondary malignancy risk was detected. In terms of SIR with different follow-up intervals, there was no difference in SIR (>6 months; <5 years) (SIR = 1.19, 95% CI 0.75-1.89) and SIR (>5 years; <10 years) (SIR = 1.39, 95% CI 0.87-2.23). When the follow-up extended to >10 years, a significantly increased secondary malignancy risk was observed (SIR = 1.45, 95% CI 1.23-1.72). There is no significantly increased secondary malignancy risk in patients receiving no RT. CONCLUSION: RT is associated with increased secondary malignancy in patients with prostate cancer; this effect only become conspicuous more than 10 years after treatment. 2014 S. Karger AG, Basel.
Authors: Dario Pasalic; Deborah A Kuban; Pamela K Allen; Chad Tang; Shane M Mesko; Stephen R Grant; Alexander A Augustyn; Steven J Frank; Seungtaek Choi; Karen E Hoffman; Quynh-Nhu Nguyen; Sean E McGuire; Alan Pollack; Mitchell S Anscher Journal: Int J Radiat Oncol Biol Phys Date: 2019-03-02 Impact factor: 7.038
Authors: Felix Preisser; Elio Mazzone; Sophie Knipper; Sebastiano Nazzani; Marco Bandini; Shahrokh F Shariat; Michele Marchioni; Zhe Tian; Fred Saad; Daniel Taussky; Alberto Briganti; Hartwig Huland; Markus Graefen; Derya Tilki; Pierre I Karakiewicz Journal: Can Urol Assoc J Date: 2019-11-29 Impact factor: 1.862
Authors: Christopher J D Wallis; Alyson L Mahar; Richard Choo; Sender Herschorn; Ronald T Kodama; Prakesh S Shah; Cyril Danjoux; Steven A Narod; Robert K Nam Journal: BMJ Date: 2016-03-02
Authors: Alexia Vogt; Sabine Schmid; Karl Heinimann; Harald Frick; Christian Herrmann; Thomas Cerny; Aurelius Omlin Journal: ESMO Open Date: 2017-05-02